Brief: Enlivex Selected By Israel Innovation Authority For $1.5 Mln Grant To Fund COVID-19 And Sepsis Clinical Trials
13/04/2020 13:37
April 13 (Reuters) - Enlivex Therapeutics Ltd ENLV.TA :
* ENLIVEX SELECTED BY THE ISRAEL INNOVATION AUTHORITY TO
RECEIVE
$1.5 MILLION GRANT TO FUND COVID-19 AND SEPSIS CLINICAL TRIALS
* ENLIVEX THERAPEUTICS - IIA SELECTED CO'S PLANNED COVID-19
&
SEPSIS CLINICAL PROGRAMS TO RECEIVE ABOUT $1.5 MILLION GRANT FOR
PERIOD THROUGH Q1 2021
Source text for Eikon: ID:nGNX3XbmMN
Further company coverage: ENLV.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Enlivex
See all newsBrief: Enlivex Ltd Registers Up To 23,333,333 Ordinary Shares For Resale By Selling Shareholder
Brief: Enlivex Announces Second Regulatory Approval For Phase 2B Trial Of Allocetra In Age-Related Primary Moderate-To-Severe Knee Osteoarthritis
Brief: Enlivex Therapeutics Files For Offering Of Up To $299.6 Mln Of Ordinary Shares
Brief: Enlivex Announces Positive 6-Month Topline Data For Patients with Knee Osteoarthritis
Brief: Enlivex Files Patent for Allocetra Use in Osteoarthritis Treatment